888CHEM
Natco Pharma to raise stake in Adcock Ingram to 49% with ₹1,400 crore investment
This acquisition is valued at ₹1,069 crore at the prevailing exchange rate and will take Hyderabad-based Natco's shareholding in Adcock Ingram from 35.75 percent to 49 percent, the company said in a emit.
Adcock Ingram has delivered a topline of $423 million with an EBITDA of $59 million to the period ending 9 months on March 31, 2026. Post transaction, NATCO will be recognising 49 percent of profit after tax of Adcock Ingram in its books.
Published on July 8, 2026
Get a Free Quote
Request a Quote
